Switch theme
Sign up to access all valuation multiples
CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C and antibiotics.
1992
21.4K+
LTM Revenue $4.4B
LTM EBITDA $1.1B
$10.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CSPC Pharma Group has a last 12-month revenue (LTM) of $4.4B and a last 12-month EBITDA of $1.1B.
In the most recent fiscal year, CSPC Pharma Group achieved revenue of $3.7B and an EBITDA of $889M.
CSPC Pharma Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CSPC Pharma Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.4B | XXX | $3.7B | XXX | XXX | XXX |
| Gross Profit | $3.1B | XXX | $2.6B | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $1.1B | XXX | $889M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| EBIT | $895M | XXX | $685M | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $708M | XXX | $552M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, CSPC Pharma Group's stock price is HKD 8 (or $1).
CSPC Pharma Group has current market cap of HKD 92.5B (or $11.8B), and EV of HKD 84.1B (or $10.7B).
See CSPC Pharma Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.7B | $11.8B | XXX | XXX | XXX | XXX | $0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, CSPC Pharma Group has market cap of $11.8B and EV of $10.7B.
CSPC Pharma Group's trades at 2.9x EV/Revenue multiple, and 12.1x EV/EBITDA.
Equity research analysts estimate CSPC Pharma Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CSPC Pharma Group has a P/E ratio of 18.1x.
See valuation multiples for CSPC Pharma Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11.8B | XXX | $11.8B | XXX | XXX | XXX |
| EV (current) | $10.7B | XXX | $10.7B | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | 10.8x | XXX | 12.1x | XXX | XXX | XXX |
| EV/EBIT | 13.0x | XXX | 15.7x | XXX | XXX | XXX |
| EV/Gross Profit | 3.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 18.1x | XXX | 21.4x | XXX | XXX | XXX |
| EV/FCF | 29.8x | XXX | 45.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCSPC Pharma Group's last 12 month revenue growth is 5%
CSPC Pharma Group's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
CSPC Pharma Group's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CSPC Pharma Group's rule of X is 37% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for CSPC Pharma Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | 1% | XXX | XXX | XXX |
| Rule of 40 | 32% | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 30% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CSPC Pharma Group acquired XXX companies to date.
Last acquisition by CSPC Pharma Group was XXXXXXXX, XXXXX XXXXX XXXXXX . CSPC Pharma Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was CSPC Pharma Group founded? | CSPC Pharma Group was founded in 1992. |
| Where is CSPC Pharma Group headquartered? | CSPC Pharma Group is headquartered in Hong Kong. |
| How many employees does CSPC Pharma Group have? | As of today, CSPC Pharma Group has 21.4K+ employees. |
| Who is the CEO of CSPC Pharma Group? | CSPC Pharma Group's CEO is Mr. Cuilong Zhang. |
| Is CSPC Pharma Group publicy listed? | Yes, CSPC Pharma Group is a public company listed on HKG. |
| What is the stock symbol of CSPC Pharma Group? | CSPC Pharma Group trades under 01093 ticker. |
| When did CSPC Pharma Group go public? | CSPC Pharma Group went public in 1994. |
| Who are competitors of CSPC Pharma Group? | Similar companies to CSPC Pharma Group include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of CSPC Pharma Group? | CSPC Pharma Group's current market cap is $11.8B |
| What is the current revenue of CSPC Pharma Group? | CSPC Pharma Group's last 12 months revenue is $4.4B. |
| What is the current revenue growth of CSPC Pharma Group? | CSPC Pharma Group revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of CSPC Pharma Group? | Current revenue multiple of CSPC Pharma Group is 2.6x. |
| Is CSPC Pharma Group profitable? | Yes, CSPC Pharma Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of CSPC Pharma Group? | CSPC Pharma Group's last 12 months EBITDA is $1.1B. |
| What is CSPC Pharma Group's EBITDA margin? | CSPC Pharma Group's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of CSPC Pharma Group? | Current EBITDA multiple of CSPC Pharma Group is 10.8x. |
| What is the current FCF of CSPC Pharma Group? | CSPC Pharma Group's last 12 months FCF is $392M. |
| What is CSPC Pharma Group's FCF margin? | CSPC Pharma Group's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of CSPC Pharma Group? | Current FCF multiple of CSPC Pharma Group is 29.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
